Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actemra in Severe COVID-19
NCT04560205Phase 1Unknown
- Sponsor
- Lahore General Hospital
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by Lahore General Hospital. Primary endpoint: Clinical response after administration at 10 days. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04560205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560205.